Developer docs
API playgroundTry for free, no card

Search company profiles

Neogene Therapeutics

Full company profile

uuid00028c3

Namestring
Neogene Therapeutics
Legal namestring
Neogene Therapeutics
Websiteurl
neogene.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Neogene Therapeutics was a private biotechnology company founded in 2018, headquartered in Amsterdam with US operations, that developed engineered T-cell receptor (TCR) therapies targeting neoantigens for the treatment of solid tumors. The company's core technology centered on redirecting patient T-cells to recognize cancer-specific neoantigens — mutated proteins unique to tumor cells — addressing a significant unmet need in oncology where conventional therapies often fail. Its product portfolio included a TCR-T cell therapy platform using autologous immune cells and personalized neoantigen cancer vaccines designed to stimulate immune responses against individual tumor profiles.

Neogene operated as a pre-commercial, clinical-stage biotech funded entirely by venture capital, raising approximately $125 million across a 2019 seed/early round and a 2020 Series B led by EcoR1 Capital, Jeito Capital, and Syncona Partners. The company had 51-100 employees and no commercial revenue or pricing model; its value was derived from proprietary TCR engineering IP, neoantigen target identification capabilities, and scientific leadership including co-founder Ton Schumacher, a prominent T-cell biology researcher. The intended end users were oncology patients with solid tumors who had exhausted existing treatment options.

In January 2023, AstraZeneca acquired Neogene for $320 million to strengthen its TCR-T therapy capabilities and accelerate solid tumor oncology pipeline development. Post-acquisition, Neogene operates as a subsidiary within AstraZeneca's oncology portfolio, and its standalone commercial trajectory is subsumed by the parent's drug development program.

Short descriptiontext

Neogene Therapeutics is a biotech company developing engineered T-cell receptor therapies and personalized neoantigen vaccines targeting solid tumors. Acquired by AstraZeneca in January 2023 for $320 million, it serves oncology patients with limited treatment options.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAmsterdam, Netherlands
HQ citystring
Amsterdam
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
TCR cell therapy, neoantigen vaccines, cancer immunotherapy, solid tumor treatment, personalized cell therapy
Industry3 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy / TCR Immunotherapy
No data
Cost components4 values
Personnel, Technology or R&D, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Neogene Therapeutics develops engineered T-cell receptor (TCR) therapies and personalized neoantigen-based cancer vaccines designed to redirect patient immune cells to recognize and attack solid tumor cancers. The company's pipeline targets cancer-specific neoantigens—mutated proteins unique to tumor cells—via TCR-engineered T-cells and individualized vaccine constructs for oncology indications.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Neogene Therapeutics is a US biotechnology company acquired by AstraZeneca in January 2023 for $320 million. The company specializes in developing T-cell receptor (TCR) therapies and personalized cancer vaccines targeting solid tumors. Its core offerings include neoantigen-based personalized cancer vaccines and TCR-T cell therapies designed to harness the patient's own immune system to recognize and destroy cancer cells.

Product and service1 record
1T-cell Receptor (TCR) Therapies
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Adaptimmune develops engineered TCR-T cell therapies for solid tumors and is the most direct comparable, having received FDA approval for Tecelra in synovial sarcoma; it competes head-to-head with Neogene in the same modality and indication space.

TypeDirect peer
Description

Immunocore develops TCR-based therapeutics, including the approved ImmTAC molecule tebentafusp, and pursues TCR candidates against solid-tumor targets—directly comparable to Neogene's TCR platform and neoantigen focus.

TypeDirect peer
Description

Immatics uses TCR-based and TCR-engineered cell therapy approaches (ACTengine, ACTallo) targeting tumor-specific antigens for solid tumors, overlapping directly with Neogene's TCR-T modality and solid-tumor focus.

TypeDirect peer
Description

TScan discovers TCRs against neoantigens and develops TCR-T therapies for solid tumors and hematologic malignancies—a close parallel to Neogene's TCR discovery-to-therapy pipeline.

TypeDirect peer
Description

Neon (acquired by BioNTech) developed personalized neoantigen vaccines and TCR-T cell therapies—virtually identical in scope to Neogene's dual modality platform and a directly comparable reference point.

TypeBroad incumbent
Description

BioNTech acquired Neon Therapeutics and runs a sizable personalized neoantigen vaccine and TCR program, operating at much greater scale with overlapping mechanism but broader portfolio scope.

TypeBroad incumbent
Description

Moderna develops mRNA-based personalized neoantigen cancer vaccines (e.g., mRNA-4157) and is a major peer in the personalized cancer vaccine space, with substantially larger resources and Phase 3 programs.

TypeEmerging player
Description

Gritstone develops personalized neoantigen cancer vaccines using viral vectors and self-amplifying mRNA, representing a comparable approach to Neogene's vaccine arm with a more focused, smaller-scale operation.

TypeBroad incumbent
Description

Iovance commercializes tumor-infiltrating lymphocyte (TIL) therapy for solid tumors—an adjacent cell-therapy modality for the same patient population Neogene targets with TCR-T.

TypeEmerging player
Description

Allogene develops allogeneic CAR-T therapies; while mechanistically different, it is a peer in the engineered T-cell therapy space targeting oncology with a contrasting off-the-shelf approach versus Neogene's autologous TCR-T.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neogene Therapeutics

Cell Therapy / TCR Immunotherapyneogene.com

Neogene Therapeutics is a biotech company developing engineered T-cell receptor therapies and personalized neoantigen vaccines targeting solid tumors. Acquired by AstraZeneca in January 2023 for $320 million, it serves oncology patients with limited treatment options.

What Neogene Therapeutics does

Neogene Therapeutics was a private biotechnology company founded in 2018, headquartered in Amsterdam with US operations, that developed engineered T-cell receptor (TCR) therapies targeting neoantigens for the treatment of solid tumors. The company's core technology centered on redirecting patient T-cells to recognize cancer-specific neoantigens — mutated proteins unique to tumor cells — addressing a significant unmet need in oncology where conventional therapies often fail. Its product portfolio included a TCR-T cell therapy platform using autologous immune cells and personalized neoantigen cancer vaccines designed to stimulate immune responses against individual tumor profiles.

Neogene operated as a pre-commercial, clinical-stage biotech funded entirely by venture capital, raising approximately $125 million across a 2019 seed/early round and a 2020 Series B led by EcoR1 Capital, Jeito Capital, and Syncona Partners. The company had 51-100 employees and no commercial revenue or pricing model; its value was derived from proprietary TCR engineering IP, neoantigen target identification capabilities, and scientific leadership including co-founder Ton Schumacher, a prominent T-cell biology researcher. The intended end users were oncology patients with solid tumors who had exhausted existing treatment options.

In January 2023, AstraZeneca acquired Neogene for $320 million to strengthen its TCR-T therapy capabilities and accelerate solid tumor oncology pipeline development. Post-acquisition, Neogene operates as a subsidiary within AstraZeneca's oncology portfolio, and its standalone commercial trajectory is subsumed by the parent's drug development program.

Neogene Therapeutics firmographics

Firmographics
Name
Neogene Therapeutics
Legal name
Neogene Therapeutics
Website
https://neogene.com
Company type
Private
Founded year
2018
Operating status
Acquired
Headcount range
11–50 employees
Short description
Neogene Therapeutics is a biotech company developing engineered T-cell receptor therapies and personalized neoantigen vaccines targeting solid tumors. Acquired by AstraZeneca in January 2023 for $320 million, it serves oncology patients with limited treatment options.
Ownership category
akta.pro rank

Neogene Therapeutics industry classification

Industry
Product category
Cell Therapy / TCR Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)

Keywords

  • TCR cell therapy
  • Neoantigen vaccines
  • Cancer immunotherapy
  • Solid tumor treatment
  • Personalized cell therapy

Where Neogene Therapeutics is headquartered

Location

Headquarters

HQ city
Amsterdam
HQ country
Netherlands
HQ region
Europe

Markets served

Neogene Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain

Neogene Therapeutics product offering

Product offering

Core offering

Neogene Therapeutics develops engineered T-cell receptor (TCR) therapies and personalized neoantigen-based cancer vaccines designed to redirect patient immune cells to recognize and attack solid tumor cancers. The company's pipeline targets cancer-specific neoantigens—mutated proteins unique to tumor cells—via TCR-engineered T-cells and individualized vaccine constructs for oncology indications.

Product overview

Neogene Therapeutics is a US biotechnology company acquired by AstraZeneca in January 2023 for $320 million. The company specializes in developing T-cell receptor (TCR) therapies and personalized cancer vaccines targeting solid tumors. Its core offerings include neoantigen-based personalized cancer vaccines and TCR-T cell therapies designed to harness the patient's own immune system to recognize and destroy cancer cells.

Differentiator

Problem solved

Functional benefit

Products and services

  • T-cell Receptor (TCR) Therapies

Companies that use Neogene Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Neogene Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Neogene Therapeutics partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights4 records

Neogene Therapeutics competitors and assessment

Company assessment

Direct peers

  • Adaptimmune: Adaptimmune develops engineered TCR-T cell therapies for solid tumors and is the most direct comparable, having received FDA approval for Tecelra in synovial sarcoma; it competes head-to-head with Neogene in the same modality and indication space.
  • Immunocore: Immunocore develops TCR-based therapeutics, including the approved ImmTAC molecule tebentafusp, and pursues TCR candidates against solid-tumor targets—directly comparable to Neogene's TCR platform and neoantigen focus.
  • Immatics: Immatics uses TCR-based and TCR-engineered cell therapy approaches (ACTengine, ACTallo) targeting tumor-specific antigens for solid tumors, overlapping directly with Neogene's TCR-T modality and solid-tumor focus.
  • TScan Therapeutics: TScan discovers TCRs against neoantigens and develops TCR-T therapies for solid tumors and hematologic malignancies—a close parallel to Neogene's TCR discovery-to-therapy pipeline.
  • Neon Therapeutics: Neon (acquired by BioNTech) developed personalized neoantigen vaccines and TCR-T cell therapies—virtually identical in scope to Neogene's dual modality platform and a directly comparable reference point.

Broad incumbents

  • BioNTech: BioNTech acquired Neon Therapeutics and runs a sizable personalized neoantigen vaccine and TCR program, operating at much greater scale with overlapping mechanism but broader portfolio scope.
  • Moderna: Moderna develops mRNA-based personalized neoantigen cancer vaccines (e.g., mRNA-4157) and is a major peer in the personalized cancer vaccine space, with substantially larger resources and Phase 3 programs.
  • Iovance Biotherapeutics: Iovance commercializes tumor-infiltrating lymphocyte (TIL) therapy for solid tumors—an adjacent cell-therapy modality for the same patient population Neogene targets with TCR-T.

Emerging players

  • Gritstone bio: Gritstone develops personalized neoantigen cancer vaccines using viral vectors and self-amplifying mRNA, representing a comparable approach to Neogene's vaccine arm with a more focused, smaller-scale operation.
  • Allogene Therapeutics: Allogene develops allogeneic CAR-T therapies; while mechanistically different, it is a peer in the engineered T-cell therapy space targeting oncology with a contrasting off-the-shelf approach versus Neogene's autologous TCR-T.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Neogene Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neogene Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

Neogene Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neogene Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neogene Therapeutics

What does Neogene Therapeutics do?

Neogene Therapeutics develops engineered T-cell receptor (TCR) therapies and personalized neoantigen-based cancer vaccines designed to redirect patient immune cells to recognize and attack solid tumor cancers. The company's pipeline targets cancer-specific neoantigens—mutated proteins unique to tumor cells—via TCR-engineered T-cells and individualized vaccine constructs for oncology indications.

Is Neogene Therapeutics a public or private company?

Neogene Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Neogene Therapeutics founded?

Neogene Therapeutics was founded in 2018. It employs 11 to 50 people.

Where is Neogene Therapeutics based?

Neogene Therapeutics is headquartered in Amsterdam, Netherlands, in the Europe region.

Who are Neogene Therapeutics's main competitors?

Direct peers on record are Adaptimmune, Immunocore, Immatics, TScan Therapeutics and Neon Therapeutics. Broad incumbents are BioNTech, Moderna and Iovance Biotherapeutics. Emerging players are Gritstone bio and Allogene Therapeutics.

Does Neogene Therapeutics have an API?

No public API is recorded for Neogene Therapeutics.

What industry is Neogene Therapeutics in?

Neogene Therapeutics's product category is Cell Therapy / TCR Immunotherapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European Biotechnology8 European VC firms to watch in 2026Eight European VC firms are profiled for 2026, including Jeito Capital, Sofinnova Partners, and Medicxi, with fund sizes and recent exits. The list highlights firms that closed new biotech funds in the past year, such as Jeito II at $1.2 billion and Medicxi V at €500 million. The firms are positioned as shaping the continent's investment landscape amid tighter capital.openPR.comIn-Depth Examination of Segments, Industry Trends, and Key Competitors in the Cellular Immunotherapy MarketThe Business Research Company published a market report on the global cellular immunotherapy sector, projecting it will grow to $12.5 billion by 2030 at a CAGR of 13.7%, driven by CAR-T therapy expansion, NK cell breakthroughs, and increased oncology investment. The report details market segmentation by therapy type, primary indication, and application area. In January 2023, AstraZeneca acquired US biotechnology firm Neogene Therapeutics for an undisclosed sum to bolster its oncology portfolio and accelerate development of T-cell receptor therapies targeting solid tumors.AstrazenecaCell TherapyAstraZeneca is advancing its cell therapy pipeline, including CAR T and TCR T therapies, to treat cancers and immune-mediated diseases through internal R&D and strategic partnerships. The company has expanded its global manufacturing footprint with new facilities in the US and China, supported by acquisitions of Gracell, Neogene, and EsoBiotec to enhance its technological capabilities.PulseforinnovationLife Sciences M&A Fuels Domestic ManufacturingThe article argues that mergers and acquisitions in the U.S. life sciences sector drive domestic manufacturing by enabling companies to access necessary production infrastructure. It highlights AstraZeneca's 2022 acquisition of Neogene Therapeutics as a primary example, noting that this deal facilitated significant investment in American facilities, including a $300 million expansion in Maryland. The piece concludes that such partnerships are essential for scaling innovations and should be supported by policymakers.OncologypipelineAstra’s Neogene investment nosedivesAstraZeneca disclosed multiple project discontinuations and trial delays in its second-quarter results, most notably the loss of NT-125 from its $200m 2022 acquisition of Neogene and delays to the Datroway TROP2 ADC program. The phase 3 Avanzar trial testing Datroway plus Infinzi and chemo in first-line EGFR-mutated NSCLC has been pushed back to the first half of 2026, while Tropion-Breast02 data in first-line TNBC is now expected in the second half of 2025. AstraZeneca also discontinued two CAR-T projects, AZD6422 and AZD5851, though the company retains other pipeline assets in these therapeutic areas through partnerships and recent acquisitions including Gracell and EsoBiotec.PR NewswireBreakthrough Properties ontwikkelt nieuw Europees hoofdkantoor voor Neogene TherapeuticsBreakthrough Properties, a joint venture between Tishman Speyer and Bellco Capital, has reached an agreement with Neogene Therapeutics to develop a new European headquarters on the Amsterdam UMC campus, with ground work beginning in August ahead of the five-story facility's planned completion in summer 2025. The facility, called Kavel F by Breakthrough, will serve Neogene—a clinical-stage biotech company and wholly-owned subsidiary of AstraZeneca pioneering T-cell receptor therapies for solid cancers—and aims to become one of the world's most advanced sustainable laboratory environments, targeting CO2-negative operations and BREEAM Outstanding certification. The project was secured after a competitive bidding process, with De Vries and Verburg as main contractor and UNStudio as architect.PR NewswireBreakthrough Properties to Develop New European Headquarters for Neogene TherapeuticsBreakthrough Properties announced an agreement with Neogene Therapeutics to develop its new European headquarters within the Amsterdam University Medical Center campus, with the five-story facility breaking ground in August. The development, called Kavel F by Breakthrough, is a 100% pre-leased project targeting BREEAM Outstanding certification and carbon-negative operations, with completion scheduled for summer 2025. Neogene Therapeutics, a clinical-stage biotechnology company and wholly-owned subsidiary of AstraZeneca, will occupy the facility as it advances its development of next-generation engineered T cell receptor therapies for solid cancers.PR NewswireGlobal Cell & Gene Therapy Business and Investment Opportunities Q1 2023 Update: An Expanding CGT Pipeline Bodes Well for GrowthResearchAndMarkets.com released its Q1 2023 update on the global cell and gene therapy market, highlighting that over 1,000 clinical trials are underway including 200 in Phase III, with six FDA-approved CAR-T cell therapies currently available for blood cancer patients. AstraZeneca announced the acquisition of clinical-stage biotech Neogene Therapeutics to strengthen its T-cell receptor treatment pipeline, while 2seventy bio projected Abecma U.S. sales of $470-570M in 2023 with anticipated label expansion. Regulatory developments including new FDA gene therapy programs and EU pharmaceutical legislation updates are expected to shape the industry's growth trajectory toward the projected 10-20 annual approvals by 2025.news.cision.comBioStock: Elicera on AstraZeneca’s acquisition of Neogene TherapeuticsAstraZeneca acquired Neogene Therapeutics, a developer of T-cell receptor therapies. Elicera Therapeutics CEO Jamal El-Mosleh commented on the acquisition's importance for the cell and gene therapy field. The company's interest in cell therapies is rising, as noted in the interview.